RU2018113694A - Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23 - Google Patents
Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23 Download PDFInfo
- Publication number
- RU2018113694A RU2018113694A RU2018113694A RU2018113694A RU2018113694A RU 2018113694 A RU2018113694 A RU 2018113694A RU 2018113694 A RU2018113694 A RU 2018113694A RU 2018113694 A RU2018113694 A RU 2018113694A RU 2018113694 A RU2018113694 A RU 2018113694A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- level
- lcn2
- disease
- paragraphs
- Prior art date
Links
- 108010065637 Interleukin-23 Proteins 0.000 title claims 32
- 102000013264 Interleukin-23 Human genes 0.000 title claims 32
- 239000005557 antagonist Substances 0.000 title claims 15
- 230000004044 response Effects 0.000 title claims 3
- 239000000090 biomarker Substances 0.000 title claims 2
- 102000013519 Lipocalin-2 Human genes 0.000 claims 41
- 108010051335 Lipocalin-2 Proteins 0.000 claims 41
- 102100030703 Interleukin-22 Human genes 0.000 claims 39
- 108010074109 interleukin-22 Proteins 0.000 claims 39
- 238000000034 method Methods 0.000 claims 32
- 229940124829 interleukin-23 Drugs 0.000 claims 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 13
- 230000001404 mediated effect Effects 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 230000001900 immune effect Effects 0.000 claims 6
- 102100024484 Codanin-1 Human genes 0.000 claims 4
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000013691 Interleukin-17 Human genes 0.000 claims 2
- 108050003558 Interleukin-17 Proteins 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 230000036541 health Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100026887 Beta-defensin 103 Human genes 0.000 claims 1
- 102100026886 Beta-defensin 104 Human genes 0.000 claims 1
- 102100038326 Beta-defensin 4A Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 1
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 102100023795 Elafin Human genes 0.000 claims 1
- 108010015972 Elafin Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 claims 1
- 101000912243 Homo sapiens Beta-defensin 104 Proteins 0.000 claims 1
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 claims 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 1
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 claims 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 claims 1
- 101000642478 Homo sapiens Serpin B3 Proteins 0.000 claims 1
- -1 IL- 21 Proteins 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 claims 1
- 101710187487 Interleukin-12 subunit beta Proteins 0.000 claims 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims 1
- 102100036679 Interleukin-26 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000001691 Member 3 Group F Nuclear Receptor Subfamily 1 Human genes 0.000 claims 1
- 108010029279 Member 3 Group F Nuclear Receptor Subfamily 1 Proteins 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 101000912227 Pan troglodytes Beta-defensin 104A Proteins 0.000 claims 1
- 208000005228 Pericardial Effusion Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 102100029812 Protein S100-A12 Human genes 0.000 claims 1
- 102100032446 Protein S100-A7 Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 claims 1
- 108700016890 S100A12 Proteins 0.000 claims 1
- 101150097337 S100A12 gene Proteins 0.000 claims 1
- 102100036383 Serpin B3 Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229960002874 briakinumab Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229950010864 guselkumab Drugs 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000004912 pericardial fluid Anatomy 0.000 claims 1
- 230000003285 pharmacodynamic effect Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000004910 pleural fluid Anatomy 0.000 claims 1
- 229950007943 risankizumab Drugs 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220062P | 2015-09-17 | 2015-09-17 | |
| US62/220,062 | 2015-09-17 | ||
| PCT/US2016/052060 WO2017049035A1 (en) | 2015-09-17 | 2016-09-16 | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018113694A true RU2018113694A (ru) | 2019-10-17 |
| RU2018113694A3 RU2018113694A3 (enExample) | 2020-01-31 |
Family
ID=58289919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018113694A RU2018113694A (ru) | 2015-09-17 | 2016-09-16 | Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11016099B2 (enExample) |
| EP (1) | EP3349854A4 (enExample) |
| JP (3) | JP6909208B2 (enExample) |
| KR (1) | KR20180063127A (enExample) |
| CN (2) | CN108290058B (enExample) |
| AU (1) | AU2016323579A1 (enExample) |
| BR (1) | BR112018005175A2 (enExample) |
| CA (1) | CA2998349A1 (enExample) |
| HK (1) | HK1258292A1 (enExample) |
| IL (1) | IL257969A (enExample) |
| MX (1) | MX2018003376A (enExample) |
| RU (1) | RU2018113694A (enExample) |
| WO (1) | WO2017049035A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| US10370718B2 (en) | 2014-09-29 | 2019-08-06 | Immusant, Inc. | Use of HLA genetic status to assess or select treatment of celiac disease |
| CN108290058B (zh) | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| WO2019113037A1 (en) * | 2017-12-04 | 2019-06-13 | Immusant, Inc. | Measurement of ccl20 after gluten exposure |
| MX2020005861A (es) * | 2017-12-07 | 2020-10-28 | Amgen Inc | Método para tratar la púrpura tombocitopénica idiopática (pti) con romiplostim. |
| CA3092551A1 (en) * | 2018-03-05 | 2019-09-12 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
| WO2019220412A2 (en) * | 2018-05-18 | 2019-11-21 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
| EP3824295A4 (en) * | 2018-07-18 | 2022-04-27 | Janssen Biotech, Inc. | PREDICTORS OF PROLONGED RESPONSE AFTER TREATMENT WITH AN ANTI-IL23 SPECIFIC ANTIBODY |
| FI13575Y1 (fi) * | 2018-09-24 | 2024-03-26 | Janssen Biotech Inc | IL12/IL23-vasta-aine käytettäväksi turvallisessa ja tehokaassa menetelmässä haavaisen paksusuolitulehduksen hoitamiseksi |
| EP3884276A2 (en) * | 2018-11-23 | 2021-09-29 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
| CN109337974B (zh) * | 2018-12-14 | 2022-01-25 | 北京蛋白质组研究中心 | 一种检测银屑病的诊断标志物的试剂及其应用 |
| WO2020128864A1 (en) * | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
| KR20210141583A (ko) * | 2019-03-18 | 2021-11-23 | 얀센 바이오테크 인코포레이티드 | 항-il-12/il-23 항체를 사용한 소아 대상의 건선 치료 방법 |
| TW202102538A (zh) * | 2019-03-26 | 2021-01-16 | 美商阿斯特捷利康合作創業有限責任公司 | 適合il23拮抗劑療法的患者群體 |
| EP3956358A4 (en) * | 2019-04-17 | 2023-01-25 | Millennium Pharmaceuticals, Inc. | COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR |
| CA3138241A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| EP4017880A4 (en) * | 2019-08-21 | 2023-10-11 | Astrazeneca Collaboration Ventures, LLC | USE OF BRAZIKUMAB TO TREAT CROHN'S DISEASE |
| CN114555120A (zh) * | 2019-10-18 | 2022-05-27 | 詹森生物科技公司 | 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法 |
| CN114761561B (zh) * | 2019-11-29 | 2024-04-30 | 东洋纺株式会社 | 重组c反应蛋白 |
| KR20220143005A (ko) * | 2019-12-20 | 2022-10-24 | 노바록 바이오테라퓨틱스 리미티드 | 항-인터루킨-23 p19 항체 및 이의 사용 방법 |
| MX2022009987A (es) * | 2020-02-14 | 2022-11-10 | Janssen Biotech Inc | Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23. |
| CN111424086A (zh) * | 2020-03-19 | 2020-07-17 | 上海交通大学 | 用于胃癌诊断及预后评估的生物标记物及应用和检测试剂盒 |
| EP4596046A3 (en) | 2020-05-21 | 2025-10-22 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| AU2021365525A1 (en) * | 2020-10-23 | 2023-06-15 | Hq Han | Bifunctional antagonists of activin and tumor necrosis factor-alpha and uses thereof |
| KR20230165746A (ko) | 2020-11-30 | 2023-12-05 | 민데라 코포레이션 | 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이 |
| US20220373539A1 (en) * | 2021-05-24 | 2022-11-24 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8318754D0 (en) | 1983-07-11 | 1983-08-10 | Fagerhol M K F | Human proteins anti-sera test kits |
| US5455160A (en) | 1993-05-27 | 1995-10-03 | Fagerhol; Magne K. | Diagnostic test and kit for disease or disorders in the digestive system |
| DK0937259T3 (da) | 1996-11-01 | 2005-01-31 | Magne K Fagerhol | Fremgangsmåde til ekstraktion af proteiner |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
| US7226591B2 (en) | 2000-05-22 | 2007-06-05 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| EP1311679B1 (en) | 2000-08-24 | 2008-10-22 | Genentech, Inc. | Method for inhibiting il-22 induced pap1 |
| RU2006135119A (ru) | 2004-03-05 | 2008-04-10 | Аркемикс Корп. (Us) | Аптамеры к семейству цитокинов il-12 человека и их применение в качестве лекарственных средств для аутоиммунных заболеваний |
| CA2565701A1 (en) | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| KR100681763B1 (ko) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
| PT1896073E (pt) | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Composições, métodos e aplicações de anticorpos anti-il-23 |
| EA013506B1 (ru) | 2005-08-25 | 2010-06-30 | Эли Лилли Энд Компани | Антитело к il-23 и его применение |
| EP2354160A1 (en) | 2005-08-31 | 2011-08-10 | Schering Corporation | Engineered anti-IL-23-antibodies |
| CN101296706B (zh) | 2005-09-01 | 2011-11-30 | 先灵公司 | Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途 |
| AU2006330411B2 (en) | 2005-12-29 | 2012-07-12 | Janssen Biotech, Inc. | Human anti-IL-23 antibodies, compositions, methods and uses |
| US20070203216A1 (en) | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
| WO2007098065A2 (en) | 2006-02-17 | 2007-08-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Human sodium channel isoforms |
| WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| AU2007261019A1 (en) | 2006-06-19 | 2007-12-27 | Wyeth | Methods of modulating IL-22 and IL-17 |
| GB0613470D0 (en) | 2006-07-06 | 2006-08-16 | Ares Trading Sa | Protein |
| WO2008028044A2 (en) | 2006-08-30 | 2008-03-06 | Centocor, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel |
| CA2678863A1 (en) | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| MX2009009079A (es) | 2007-02-23 | 2009-08-31 | Schering Corp | Anticuerpos anti-il-23p19 de ingenieria. |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| CA2702590A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| US20090123946A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US20090269777A1 (en) | 2007-10-19 | 2009-10-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US20100304413A1 (en) | 2007-11-15 | 2010-12-02 | Lars Otto Uttenthal | Diagnostic use of individual molecular forms of a biomarker |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| US7833721B2 (en) | 2008-03-14 | 2010-11-16 | Exagen Diagnostics, Inc. | Biomarkers for inflammatory bowel disease and irritable bowel syndrome |
| US20100227775A1 (en) | 2008-04-16 | 2010-09-09 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| CN102202655B (zh) | 2008-08-27 | 2013-06-19 | 默沙东公司 | 基因工程抗IL-23p19抗体的冻干制剂 |
| GB2464183A (en) | 2008-09-19 | 2010-04-14 | Singulex Inc | Sandwich assay |
| EP2347256A4 (en) | 2008-10-09 | 2012-02-08 | Alfagene Bioscience Inc | USE AND IDENTIFICATION OF BIOMARKERS FOR GASTROINTESTINAL DISEASES |
| US20100105150A1 (en) | 2008-10-24 | 2010-04-29 | Abbott Laboratories | Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal |
| JP2012507723A (ja) * | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| EP2414393A1 (en) | 2009-04-01 | 2012-02-08 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| WO2010129964A1 (en) | 2009-05-08 | 2010-11-11 | The Board Of Trustees Of The University Of Illinois | Drug targets for prevention of arrhythmia in heart disease |
| EP2435480A1 (en) | 2009-05-27 | 2012-04-04 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
| CA2766157A1 (en) | 2009-06-25 | 2010-12-29 | Hua Gong | Methods for diagnosing irritable bowel syndrome |
| EP2451969A2 (en) | 2009-07-07 | 2012-05-16 | University Of Southern California | Biomarkers for the early detection of autoimmune diseases |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| PH12012501016A1 (en) | 2009-11-25 | 2013-01-14 | Prometheus Laboratories Inc | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| IN2012DN06720A (enExample) | 2010-01-15 | 2015-10-23 | Kirin Amgen Inc | |
| MX341309B (es) | 2010-07-20 | 2016-08-12 | Cephalon Australia Pty Ltd | Anticuerpos especificos del heterodimero de anti-il-23. |
| US8541180B1 (en) | 2010-10-11 | 2013-09-24 | Genova Diagnostics, Inc. | Compositions and methods for assessing gastrointestinal health |
| WO2012061448A1 (en) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
| JP6116485B2 (ja) | 2011-01-06 | 2017-04-19 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 心臓性突然死に関連する方法において使用するためのｓｃｎ５ａスプライスバリアント |
| GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
| CA2827894A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| AU2012249288C1 (en) | 2011-04-29 | 2017-12-21 | Lung Cancer Proteomics Llc | Methods of identification and diagnosis of lung diseases using classification systems and kits thereof |
| EP2710383B1 (en) | 2011-05-16 | 2017-01-11 | The University of Newcastle | Performance of a biomarker panel for irritable bowel syndrome |
| NO336551B1 (no) | 2011-06-21 | 2015-09-28 | Magne Fagerhol | Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve |
| NO20110895A1 (no) | 2011-06-21 | 2012-12-24 | Magne Fagerhol | Kompetitive S100A9 immunoanalyser |
| KR20140067001A (ko) | 2011-08-08 | 2014-06-03 | 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. | 생물지표 조성물 및 방법 |
| US9161935B2 (en) * | 2012-02-03 | 2015-10-20 | Teva Pharmaceutical Industries, Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy |
| WO2013132338A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Competitive immunoassay for calprotectin |
| WO2013132347A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Improved elisa immunoassay for calprotectin |
| US9732387B2 (en) | 2012-04-03 | 2017-08-15 | The Regents Of The University Of Michigan | Biomarker associated with irritable bowel syndrome and Crohn's disease |
| AU2013326921C1 (en) * | 2012-10-05 | 2018-01-18 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
| EP3143401A4 (en) | 2014-05-15 | 2017-10-11 | Meso Scale Technologies, LLC | Improved assay methods |
| US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| WO2016014775A1 (en) * | 2014-07-24 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of il-23a related diseases |
| CN108290058B (zh) | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| GB201521357D0 (en) | 2015-12-03 | 2016-01-20 | Univ Liverpool | Methods for predicting response to anti-TNF therapy |
| JP2019508370A (ja) | 2015-12-22 | 2019-03-28 | アムジェン インコーポレイテッド | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ |
| WO2018089693A2 (en) | 2016-11-09 | 2018-05-17 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
| WO2018119626A1 (zh) | 2016-12-27 | 2018-07-05 | 菲鹏生物股份有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
-
2016
- 2016-09-16 CN CN201680066986.XA patent/CN108290058B/zh not_active Expired - Fee Related
- 2016-09-16 BR BR112018005175A patent/BR112018005175A2/pt not_active Application Discontinuation
- 2016-09-16 HK HK19100656.4A patent/HK1258292A1/zh unknown
- 2016-09-16 KR KR1020187010308A patent/KR20180063127A/ko not_active Withdrawn
- 2016-09-16 CN CN202310427386.3A patent/CN116672446A/zh active Pending
- 2016-09-16 AU AU2016323579A patent/AU2016323579A1/en not_active Abandoned
- 2016-09-16 CA CA2998349A patent/CA2998349A1/en not_active Abandoned
- 2016-09-16 US US15/759,330 patent/US11016099B2/en active Active
- 2016-09-16 JP JP2018514414A patent/JP6909208B2/ja not_active Expired - Fee Related
- 2016-09-16 MX MX2018003376A patent/MX2018003376A/es unknown
- 2016-09-16 RU RU2018113694A patent/RU2018113694A/ru not_active Application Discontinuation
- 2016-09-16 WO PCT/US2016/052060 patent/WO2017049035A1/en not_active Ceased
- 2016-09-16 EP EP16847353.6A patent/EP3349854A4/en not_active Withdrawn
-
2018
- 2018-03-08 IL IL257969A patent/IL257969A/en unknown
-
2021
- 2021-07-02 JP JP2021110695A patent/JP7153775B2/ja active Active
-
2022
- 2022-10-03 JP JP2022159196A patent/JP2023002583A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023002583A (ja) | 2023-01-10 |
| EP3349854A1 (en) | 2018-07-25 |
| JP6909208B2 (ja) | 2021-07-28 |
| CN108290058B (zh) | 2023-05-16 |
| WO2017049035A1 (en) | 2017-03-23 |
| CA2998349A1 (en) | 2017-03-23 |
| RU2018113694A3 (enExample) | 2020-01-31 |
| CN116672446A (zh) | 2023-09-01 |
| EP3349854A4 (en) | 2019-04-03 |
| AU2016323579A1 (en) | 2018-04-05 |
| BR112018005175A2 (pt) | 2018-10-16 |
| IL257969A (en) | 2018-05-31 |
| MX2018003376A (es) | 2018-08-15 |
| HK1258292A1 (zh) | 2019-11-08 |
| JP7153775B2 (ja) | 2022-10-14 |
| JP2018535394A (ja) | 2018-11-29 |
| US20180252728A1 (en) | 2018-09-06 |
| JP2021170017A (ja) | 2021-10-28 |
| CN108290058A (zh) | 2018-07-17 |
| KR20180063127A (ko) | 2018-06-11 |
| US11016099B2 (en) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018113694A (ru) | Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23 | |
| RU2018124603A (ru) | Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23 | |
| JP2018535394A5 (enExample) | ||
| JP6563976B2 (ja) | 可溶性ヒトｓｔ−２抗体およびアッセイ法 | |
| JP2019508370A5 (enExample) | ||
| RU2658601C2 (ru) | Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба | |
| Ha et al. | Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis | |
| CN102884433A (zh) | 用于检测抗体的方法 | |
| CN104870012A (zh) | 用于炎性疾病的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 | |
| CN104838270A (zh) | 用于预测和监测粘膜愈合的方法 | |
| TWI655433B (zh) | 川崎氏症之診斷與治療 | |
| CN106526196B (zh) | Sr-a作为类风湿关节炎诊断标志物及干预靶点的应用 | |
| Krajewska et al. | Serum levels of interleukin-32 and interleukin-6 in granulomatosis with polyangiitis and microscopic polyangiitis: association with clinical and biochemical findings | |
| Haghighi et al. | CSF levels of cytokines in neuro-Behçet's disease | |
| US20190137489A1 (en) | Antibody anti il17 | |
| US20170315119A1 (en) | Urinary biomarkers for sle and lupus nephritis | |
| US20210215712A1 (en) | Serum biomarkers for predicting and evaluating response to tnf inhibitor therapy in rheumatoid arthritis patients | |
| CN114981660B (zh) | 用于具有小分子调节剂的il-17靶向接合测定的组合物和方法 | |
| AU2016269576B2 (en) | Soluble human ST-2 antibodies and assays | |
| Charlton et al. | Can Urinary Biomarkers at AKI Predict Progression to CKD?: PO0418 | |
| Mccoy et al. | Hospitalized AKI Is Associated with Long-Term Increases in TNFR1 and TNFR2: Findings from the CRIC Study: PO0417 | |
| AU2013204182B2 (en) | Soluble human ST-2 antibodies and assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20211115 |